Work

A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia

Year: 2006

Type: article

Study design: Clinical Trial

Source: Leukemia Research

DOI: 10.1016/j.leukres.2006.02.019

Authors: Francis Giles, Srdan Verstovsek, Stefan Faderl, Norbert Vey, Judy Karp, Gail Roboz, Khuda Dan Khan, Maureen Cooper, Syed Fazl Ali Bilgrami, Augustin Ferrant, Simon Daenen, Verena Karsten, Ann Cahill, Maher Albitar, Hagop Kantarjian, Susan O’Brien, Eric Feldman

Institutions: The University of Texas MD Anderson Cancer Center, Institut Paoli-Calmettes, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Cornell University, Saint Francis Hospital & Medical Center, Cliniques Universitaires Saint-Luc, UCLouvain, KU Leuven, University of Groningen, Vion Pharmaceuticals (United States), Quest Diagnostics (United States)

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2075752103

FWCI: 3.662

Cites: 23

Cited by: 25

Related to: 10